Related references
Note: Only part of the references are listed.Blood-Based Biomarkers in High Grade Gliomas: a Systematic Review
Daniela Pierscianek et al.
MOLECULAR NEUROBIOLOGY (2019)
Challenges to curing primary brain tumours
Kenneth Aldape et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Postsurgical Approaches in Low-Grade Oligodendroglioma: Is Chemotherapy Alone Still an Option?
Enrico Franceschi et al.
ONCOLOGIST (2019)
Biomarkers for Predicting Response to Immunotherapy with Immune Checkpoint Inhibitors in Cancer Patients
Michael J. Duffy et al.
CLINICAL CHEMISTRY (2019)
Baseline Absolute Lymphocyte Count and ECOG Performance Score Are Associated with Survival in Advanced Non-Small Cell Lung Cancer Undergoing PD-1/PD-L1 Blockade
Florian Huemer et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Liquid Biopsy in Glioblastoma: Opportunities, Applications and Challenges
Ander Saenz-Antonanzas et al.
CANCERS (2019)
Progenostic value of preoperative hematological markers combined with molecular pathology in patients with diffuse gliomas
Zhen-Yu Zhang et al.
AGING-US (2019)
The prognostic role of preoperative systemic immune-inflammation index and albumin/globulin ratio in patients with newly diagnosed high-grade glioma
Ruofei Liang et al.
CLINICAL NEUROLOGY AND NEUROSURGERY (2019)
Soluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in Gastric Cancer: Direct Comparison of the Clinical Burden Between Tissue and Serum PD-L1 Expression
Tsunehiko Shigemori et al.
ANNALS OF SURGICAL ONCOLOGY (2019)
Soluble Programmed Death Receptor Ligands sPD-L1 and sPD-L2 as Liquid Biopsy Markers for Prognosis and Platinum Response in Epithelial Ovarian Cancer
Paul Buderath et al.
FRONTIERS IN ONCOLOGY (2019)
Soluble Ligand of the Immune Checkpoint Receptor (sPD-L1) in Blood Serum of Patients with Renal Cell Carcinoma
N. E. Kushlinskii et al.
BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE (2019)
Circulating tumour DNA, microRNA and metabolites in cerebrospinal fluid as biomarkers for central nervous system malignancies
Soheil Zorofchian et al.
JOURNAL OF CLINICAL PATHOLOGY (2019)
Dynamics of Soluble Programmed Death-Ligand 1 (sPDL1) during Chemotherapy and Its Prognostic Implications in Cancer Patients: Biomarker Development in Immuno-oncology
Hyerim Ha et al.
CANCER RESEARCH AND TREATMENT (2019)
Soluble programmed death-ligand 1 are highly expressed in peripheral T-cell lymphoma: a biomarker for prognosis
Haorui Shen et al.
HEMATOLOGY (2019)
Influence of neutrophil-lymphocyte ratio in prognosis of glioblastoma multiforme
Marta Lopes et al.
JOURNAL OF NEURO-ONCOLOGY (2018)
Sex-dependent association of preoperative hematologic markers with glioma grade and progression
Wenshen Xu et al.
JOURNAL OF NEURO-ONCOLOGY (2018)
Diagnostic value of preoperative inflammatory markers in patients with glioma: a multicenter cohort study
Shi-hao Zheng et al.
JOURNAL OF NEUROSURGERY (2018)
Programmed death-ligand 1 is a promising blood marker for predicting tumor progression and prognosis in patients with gastric cancer
Masahiko Amatatsu et al.
CANCER SCIENCE (2018)
Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non-Small-cell Lung Cancer
Yusuke Okuma et al.
CLINICAL LUNG CANCER (2018)
The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers
Kazuki Takada et al.
CLINICAL LUNG CANCER (2018)
Peripheral Blood Biomarkers Associated with Clinical Outcome in Non-Small Cell Lung Cancer Patients Treated with Nivolumab
Junko Tanizaki et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Evolving Insights into the Molecular Neuropathology of Diffuse Gliomas in Adults
Floris P. Barthel et al.
NEUROLOGIC CLINICS (2018)
PD-L1 expression in pleural effusions of pulmonary adenocarcinoma and survival prediction: a controlled study by pleural biopsy
Jian Xu et al.
SCIENTIFIC REPORTS (2018)
Preoperative Changes in Hematological Markers and Predictors of Glioma Grade and Survival
Peng-Fei Wang et al.
FRONTIERS IN PHARMACOLOGY (2018)
Smoking Is Associated With Low Levels of Soluble PD-L1 in Rheumatoid Arthritis
Caroline Wasen et al.
FRONTIERS IN IMMUNOLOGY (2018)
Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies
Aixa E. Soyano et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Advances in the molecular genetics of gliomas - implications for classification and therapy
Guido Reifenberger et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma A Randomized Clinical Trial
Roger Stupp et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Immunotherapy for Brain Tumors
John H. Sampson et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Low preoperative prognostic nutritional index predicts poor survival in patients with newly diagnosed high-grade gliomas
Zhen-Qiang He et al.
JOURNAL OF NEURO-ONCOLOGY (2017)
European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas
Michael Weller et al.
LANCET ONCOLOGY (2017)
Detection of immune responses after immunotherapy in glioblastoma using PET and MRI
Joseph P. Antonios et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade
Jun Zhou et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer
Stephan Kruger et al.
ONCOIMMUNOLOGY (2017)
Retrospective review of safety and efficacy of programmed cell death-1 inhibitors in refractory high grade gliomas
Samantha N. Reiss et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Isocitrate dehydrogenase mutations in gliomas
Matthew S. Waitkus et al.
NEURO-ONCOLOGY (2016)
PD-L1 expression and prognostic impact in glioblastoma
Edjah K. Nduom et al.
NEURO-ONCOLOGY (2016)
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2016)
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab
P. F. Ferrucci et al.
ANNALS OF ONCOLOGY (2016)
Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors
Jeanette E. Eckel-Passow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma
Anna Sophie Berghoff et al.
NEURO-ONCOLOGY (2015)
The PD-1/PD-Ls pathway and autoimmune diseases
Suya Dai et al.
CELLULAR IMMUNOLOGY (2014)
Use of dexamethasone in patients with high-grade glioma: a clinical practice guideline
X. Kostaras et al.
CURRENT ONCOLOGY (2014)
Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications
Zhixue Zheng et al.
CHINESE JOURNAL OF CANCER RESEARCH (2014)
Understanding high grade glioma: Molecular mechanism, therapy and comprehensive management
Yongzhi Wang et al.
CANCER LETTERS (2013)
Glioblastoma and Other Malignant Gliomas A Clinical Review
Antonio Omuro et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Bathing the brain
Warren J. Strittmatter
JOURNAL OF CLINICAL INVESTIGATION (2013)
Seizure characteristics and outcomes in 508 Chinese adult patients undergoing primary resection of low-grade gliomas: a clinicopathological study
Gan You et al.
NEURO-ONCOLOGY (2012)
Identification of a Soluble Form of B7-H1 That Retains Immunosuppressive Activity and Is Associated with Aggressive Renal Cell Carcinoma
Xavier Frigola et al.
CLINICAL CANCER RESEARCH (2011)
Development of a sandwich ELISA for evaluating soluble PD-L1 (CD274) in human sera of different ages as well as supernatants of PD-L1+ cell lines
Yongjing Chen et al.
CYTOKINE (2011)
Detection of cancer cells in the cerebrospinal fluid: current methods and future directions
Cody L. Weston et al.
FLUIDS AND BARRIERS OF THE CNS (2011)
Monoclonal antibody specific for IDH1 R132H mutation
David Capper et al.
ACTA NEUROPATHOLOGICA (2009)
Cancer-related inflammation
Alberto Mantovani et al.
NATURE (2008)
The 2007 WHO classification of tumours of the central nervous system
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2007)
The utility of Ki-67 and BrdU as proliferative markers of adult neurogenesis
N Kee et al.
JOURNAL OF NEUROSCIENCE METHODS (2002)
Share Paper
